Table 2. Characteristics of patients with CTEPH.
| Initial PE |
During follow-up |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years)/sex | Time from symptoms to diagnosis (days) | Unprovoked PE | RV wall thickness (mm) | RV/LV | SPAP (mmHg) | ESC risk stratification | Initial therapy* | Dyspnea | Time to CTEPH (months) | RV/LV | SPAP (mmHg) | MPAP by RHC (mmHg) | WHO FC | |
| 68/F | 20 | No | 4.0 | 0.9 | 78.0 | Intermediate | Anticoagulation | Yes | 11 | 1.1 | 95.0 | 43 | IV | |
| 75/F | 3 | No | 3.9 | 0.7 | 61.5 | Low | Anticoagulation | Yes | 33 | 1.0 | 53.0 | – | II | |
| 68/M | 0 | Yes | 4.2 | 0.6 | 78.0 | Low | Anticoagulation | Yes | 13 | 0.7 | 57.0 | 45 | II | |
| 73/F | 7 | Yes | 4.8 | 1.7 | 84.0 | Intermediate | Thrombolysis | Yes | 12 | 2.1 | 97.3 | – | IV | |
| 74/F | 7 | No | 4.5 | 0.8 | 44.5 | Low | Anticoagulation | No | 23 | 0.9 | 58.5 | – | I | |
| 44/F | 31 | No | 4.5 | 1.2 | 68.0 | Intermediate | Anticoagulation | Yes | 15 | 1.3 | 46.7 | 27 | II | |
| 65/M | 7 | Yes | 4.2 | 1.1 | 74.0 | Low | Anticoagulation | Yes | 6 | 1.4 | 71.0 | 32 | II | |
| 67/F | 2 | No | 4.3 | 1.1 | 82.0 | Intermediate | Thrombolysis | Yes | 7 | 1.2 | 53.2 | – | II | |
| 69/M | 20 | Yes | 3.9 | 1.2 | 72.0 | Intermediate | Anticoagulation | Yes | 9 | 1.4 | 80.5 | – | II | |
| 80/F | 1 | No | 4.7 | 1.2 | 73.0 | Intermediate | Anticoagulation | Yes | 31 | 1.5 | 70.2 | – | II | |
*, hemodynamically stable acute PE was initially treated with either adjusted-dose unfractionated heparin or weight-based therapeutic doses of low molecular weight heparin. Hemodynamically unstable acute PE was initially treated with thrombolytic therapy, including streptokinase, urokinase, or recombinant tissue plasminogen activator. All patients (except for patients with cancer) started treatment with vitamin K antagonists within 1 week of diagnosis and continued for ≥6 months. In patients with cancer, low molecular weight heparin administered in the acute phase and continued over the first 3-6 months. CTEPH, chronic thromboembolic pulmonary hypertension; ESC, European Society for Cardiology; F, female; M, male; MPAP, mean pulmonary arterial pressure; PE, pulmonary embolism; RHC, right heart catheterization; RV, right ventricle; RV/LV, right ventricle to left ventricle end-diastolic diameter ratio; SPAP, systolic pulmonary artery pressure; WHO FC, World Health Organization functional class.